Nexium (Esomeprazole)

Nexium (esomeprazole) acts on the gastric acid secretion pathway and is indicated for several acid‑related conditions.

• Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of the esophageal lining.
• Erosive esophagitis: facilitates mucosal repair and decreases further erosion.
• NSAID‑induced gastric ulcer: protects the gastric mucosa from ulcer formation.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion.
• Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens.

• Esomeprazole irreversibly binds to the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly lowers both basal and stimulated gastric acidity, allowing ulcer healing and symptom relief in acid‑related disorders.

Adverse reactions may occur with esomeprazole use. Most are mild and self‑limiting, but rare serious events have been reported.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: watery stools, usually transient.
• Nausea: occasional upset stomach.
• Abdominal pain: cramping or discomfort.
• Flatulence: increased gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Stevens‑Johnson syndrome: skin blistering and mucosal involvement.
• Elevated liver enzymes: signs of hepatic stress.
• Hypomagnesemia: low magnesium levels with prolonged use.
• Increased risk of bone fracture: especially with long‑term therapy.

Before initiating esomeprazole, consider the following safety measures.

• Assess renal function: adjust therapy in severe impairment.
• Monitor for infection: be alert to signs of C. difficile colitis.
• Review duration of therapy: avoid unnecessary long‑term use.
• Evaluate bone health: consider calcium and vitamin D supplementation if treatment exceeds 12 months.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Esomeprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet activity, increasing cardiovascular risk.
• Atazanavir: markedly decreased absorption, compromising antiviral efficacy.
• Warfarin: potential increase in INR, enhancing bleeding risk.
• Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely)

• Digoxin: elevated serum concentrations, requiring level monitoring.
• Diazepam: increased sedation, dose adjustment may be needed.
• Phenytoin: decreased plasma levels, may reduce seizure control.